Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion type Assertion NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_head.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion wasGeneratedBy ECO_0000203 NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_provenance.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion wasDerivedFrom befree-2016 NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_provenance.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion SIO_000772 17848408 NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_provenance.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion evidence source_evidence_literature NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_provenance.
- NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_assertion description "[Nevertheless, overexpression of Bcl-2 may result in oncogene addiction of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP629485.RAkitHMso1jY_BtSI2zQMBcSUcLwq7df0cpBu-QZZbdlg130_provenance.